Headlines about Teva Pharmaceutical Industries Limited (NYSE:TEVA) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teva Pharmaceutical Industries Limited earned a news impact score of 0.09 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.729039976209 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s rankings:
- Most Active Stock: Teva Pharmaceutical Industries Limited (TEVA) (badhub.net)
- Teva Pharmaceutical Industries Limited (TEVA) Receives “Outperform” Rating from Oppenheimer Holdings, Inc (ismboard.com)
- Teva Pharmaceutical Industries Limited (NYSE:TEVA) Plans Quarterly Dividend of $0.09 (expressnewsline.com)
- Teva Pharmaceutical Industries Limited (TEVA) Stake Reduced by Barry Investment Advisors LLC (vothemes.com)
- A Long Road To Recovery For Teva Pharmaceuticals; Morgan Stanley Downgrades – Benzinga (benzinga.com)
Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 17.50 on Thursday. Teva Pharmaceutical Industries Limited has a one year low of $17.47 and a one year high of $55.39. The company has a 50-day moving average of $31.60 and a 200-day moving average of $32.12. The stock has a market capitalization of $17.78 billion, a price-to-earnings ratio of 224.36 and a beta of 0.46.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. During the same period last year, the firm earned $1.25 earnings per share. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% on a year-over-year basis. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.44 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be paid a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 1.94%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently -18.95%.
Several equities research analysts have issued reports on TEVA shares. Zacks Investment Research upgraded Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research report on Monday, April 17th. Deutsche Bank AG dropped their target price on Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, May 12th. Vetr upgraded Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $34.25 target price on the stock in a research report on Wednesday, May 17th. Citigroup Inc. dropped their target price on Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, April 25th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $38.00 price objective (down previously from $42.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, May 15th. Three analysts have rated the stock with a sell rating, nineteen have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $37.69.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2796599/teva-pharmaceutical-industries-limited-teva-getting-somewhat-favorable-media-coverage-accern-reports.html.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.